Search results: (10000)
News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.
News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis
A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.
News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations
Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.
News Risk Factors for Renal Cancer Formation After Kidney Transplantation
German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.
News Drops with Liposomal Ozonized Oil Reduce Ocular Microbial Burden Before Cataract Surgery
The periocular zone and conjunctiva are characterized by high microbial activity. Therefore, it is important to reduce this bacterial burden as part of preoperative prophylaxis before surgery to minimize the risk of infection. The aim of the study presented below, conducted in 20 Italian centers, was to evaluate the antimicrobial efficacy of a new ocular solution in patients undergoing cataract surgery.
News Hybrid Cooperative Complexes in the Treatment of Osteoarthritis
Intra-articular application of corticosteroids and hyaluronic acid is part of the treatment of osteoarthritis (OA) in patients for whom oral or topical treatment does not provide sufficient response. The following text addresses the lubricating and protective properties of synovial fluid and the related choice of appropriate intra-articular viscosupplementation, with emphasis on innovative molecules with high concentrations of hyaluronic acid and low viscosity.
News Combined Treatment of Chronic Lymphocytic Leukemia in Frail Patients – Results from Real-World Clinical Practice
Treatment of older patients and those with chronic lymphocytic leukemia (CLL) who are not in good physical condition has advanced significantly in recent years. The addition of obinutuzumab to chlorambucil therapy has extended both progression-free survival and overall survival for patients. The authors of the presented study evaluated the efficacy and safety of obinutuzumab in real-world clinical practice.
News Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven activating mutation of the epidermal growth factor receptor (EGFR) gene, who developed resistance to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib during treatment. After the secondary mutation EGFR T790M was confirmed, osimertinib, a third-generation EGFR TKI, was introduced, resulting in disease regression, which is ongoing. This case study illustrates the significance of the role of osimertinib in the treatment of patients with NSCLC with an activating EGFR mutation, whose disease progresses during treatment with first and second-generation EGFR TKIs due to the emergence of the secondary EGFR T790M mutation.
News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.
News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients
The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.
News Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.
News Romiplostim in Newly Diagnosed or Persistent ITP
Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.
News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency
The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
News Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.
News Levothyroxine Substitution Depending on Patient Genotype
Careful titration of hormone dose leads to optimal dosing of replacement therapy for hypothyroidism. The authors of a cross-sectional study published in the Endocrine Journal examined the impact of polymorphisms in genes for proteins involved in thyroid hormone metabolism on the response to levothyroxine treatment in patients after thyroidectomy.
News Augmentation of Clozapine with Lurasidone in Resistant Schizophrenia in Real Practice
Treatment-resistant schizophrenia remains a clinical and pharmacological challenge. Clozapine remains the gold standard in these cases. Unfortunately, a significant portion of patients respond only partially to it. The solution is often an augmentation strategy with another atypical antipsychotic. According to current findings, adjunctive therapy with lurasidone appears promising — two recently published studies have brought interesting data.
News Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better
The recently published analysis of data from the extended open-label follow-up of participants in the PIONEER-HF study clearly pointed out the difference in outcomes and prognosis of patients, which is led by the initiation of the combined drug during hospitalization compared to its initiation shortly after discharge.
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity
A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.
News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?
The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma
Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.